Abstract
The COVID-19 pandemic has forced a rethinking of public health and patent systems. It has brought livelihoods to a halt, wreaking havoc on people's lives and national economies. The need to create and deploy additional vaccinations, repurpose pharmaceuticals, and sustain medical infrastructure is jeopardising global health security. At the international and national levels, collaboration and collaborative action are essential. In terms of public health, IPR access is critical. Many countries have announced new rules and passed legislation to make it simpler to provide medicines to their citizens during the pandemic. Compulsory licensing has been a key tool for opening up IP without the approval of patent holders.There is frequently a conflict between the need to grant monopolies in the form of IP rights as an incentive for pharmaceutical sector advancements on the one hand, and the need to award monopolies in the form of IP rights as a fundamental right on the other. As a result, hurdles exist in decision-making in order to strike a balance between innovative incentives and assuring access to healthcare.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
